title: Efficacy of vaginal danazol treatment in women with menorrhagia during fertile age.
abstract: OBJECTIVE
  To evaluate the clinical efficacy and patient satisfaction of danazol delivered vaginally as treatment for young women with menorrhagia.
  
  
  METHODS
  Prospective study.
  
  
  METHODS
  University of Siena, Siena, Italy.
  
  
  METHODS
  Women with menorrhagia (n = 55; age range 25-35 years) after ultrasound and hysteroscopy.
  
  
  METHODS
  Low-dose danazol (200 mg/day) was daily administered by vaginal route for 6 months.
  
  
  METHODS
  Before and every month during the treatment women were requested: 1) to keep a diary of menstrual bleeding and to rate blood loss on a visual analog scale from 0 (no blood loss) to 10 (gushing-type bleeding); 2) to record side effects and their satisfaction with the therapy. Transvaginal ultrasound, blood count, serum chemistries, and serum concentration of LH, FSH, E(2), TSH, FT(3), FT(4), and PRL were evaluated before and after 6 months.
  
  
  RESULTS
  The severity of blood loss was significantly reduced in all of the women after 2 months of treatment. Uterine volume was significantly reduced, and hematocrit, hemoglobin, and red blood cell count increased in all of the women after 6 months. The medical treatment did not affect hormonal parameters, and menstrual cycle remained unaffected; few local vaginal adverse effects were recorded.
  
  
  CONCLUSIONS
  Vaginal danazol resulted in effective medical treatment in young women with menorrhagia, and, because of a lack of significant adverse effects, it may be proposed as an alternative treatment.
authors.affiliation: Division of Obstetrics and Gynecology, Department of Pediatrics, Gynecology, and Reproductive Medicine, University of Siena, Siena, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Luisi
authors.affiliation: Division of Obstetrics and Gynecology, Department of Pediatrics, Gynecology, and Reproductive Medicine, University of Siena, Siena, Italy.
authors.forename: Sandro
authors.initials: S
authors.lastname: Razzi
authors.affiliation: Division of Obstetrics and Gynecology, Department of Pediatrics, Gynecology, and Reproductive Medicine, University of Siena, Siena, Italy.
authors.forename: Lucia
authors.initials: L
authors.lastname: Lazzeri
authors.affiliation: Division of Obstetrics and Gynecology, Department of Pediatrics, Gynecology, and Reproductive Medicine, University of Siena, Siena, Italy.
authors.forename: Caterina
authors.initials: C
authors.lastname: Bocchi
authors.affiliation: Division of Obstetrics and Gynecology, Department of Pediatrics, Gynecology, and Reproductive Medicine, University of Siena, Siena, Italy.
authors.forename: Filiberto M
authors.initials: FM
authors.lastname: Severi
authors.affiliation: Division of Obstetrics and Gynecology, Department of Pediatrics, Gynecology, and Reproductive Medicine, University of Siena, Siena, Italy. Electronic address: petraglia@unisi.it.
authors.forename: Felice
authors.initials: F
authors.lastname: Petraglia
mesh_terms: D000282:Administration, Intravaginal; D000328:Adult; D000367:Age Factors; D003613:Danazol / Q000008:administration & dosage*; D004906:Erythrocyte Count; D004965:Estrogen Antagonists / Q000008:administration & dosage; D005260:Female; D005298:Fertility / Q000187:drug effects* / Q000502:physiology; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008595:Menorrhagia / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D017060:Patient Satisfaction; D016896:Treatment Outcome
chemical_list: D004965:Estrogen Antagonists; D006454:Hemoglobins; D003613:Danazol